Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BI 695501 vs Adalimumab in Healthy Subjects
NCT02045979Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2014
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA), psoriasis, Crohn's disease and 6 more (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration Time Curve From Time Zero to Infinity at Day 71, Area Under the Concentration Time Curve From Time Zero to Last Measurable Concentration at Day 71 and 1 more. Started Jan 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriasisCrohn's diseaseulcerative colitis (UC)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02045979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045979.